Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Ccx354. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CCR1 known ✓ | P32246 | 20/20 | 1.00 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.51 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Ccx354 SCHEMBL30538013 | 1.00 | CCR1 (1.00) | CCR1CYP2C19KCNH2 | |
| Ccx354 SCHEMBL29364104 | 1.00 | CCR1 (1.00) | CCR1CYP2C19KCNH2 | |
| Ccx354 SCHEMBL30865101 | 1.00 | CCR1 (1.00) | CCR1CYP2C19KCNH2 | |
| SCHEMBL1638044 | 0.93 | CCR1 (0.87) | CCR1CYP2C19KCNH2 | |
| SCHEMBL10080244 | 0.91 | CCR1 (0.83) | CCR1CYP2C19KCNH2 | |
| SCHEMBL1638693 | 0.90 | CCR1 (0.82) | CCR1CYP2C19KCNH2 | |
| SCHEMBL1639499 | 0.90 | CCR1 (0.82) | CCR1CYP2C19KCNH2 | |
| SCHEMBL1638600 | 0.90 | CCR1 (0.81) | CCR1CYP2C19KCNH2 | |
| SCHEMBL1637790 | 0.88 | CCR1 (0.79) | CCR1 | |
| SCHEMBL1638041 | 0.88 | CCR1 (0.79) | CCR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 110 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250228870-A1 | CERTAIN (2S)-N-[(1S)-1-CYANO-2-PHENYLETHYL]-1,4-OXAZEPANE-2-CARBOXAMIDES FOR TREATING BRONCHIECTASIS | ASTRAZENECA AB (SE) | 2025-07-17 | — | — | US | disclosed |
| EP-4548972-A2 | (2S)-N-[(1S)-1-CYANO-2-PHENYLETHYL]-1,4-OXAZEPANE-2-CARBOXAMIDES AS DIPEPTIDYL PEPTIDASE I INHIBITORS | AstraZeneca AB (SE) | 2025-05-07 | — | — | EP | disclosed |
| US-12054465-B2 | Certain (2S)-N-[(1S)-1-cyano-2-phenylethyl]-1,4-oxazepane-2-carboxamides as dipeptidyl peptidase 1 inhibitors | ASTRAZENECA AB (SE) | 2024-08-06 | — | — | US | disclosed |
| WO-2024089691-A1 | MODULATORS AND USES THEREOF | HADASIT MEDICAL RESEARCH SERVICES AND DEVELOPMENT LTD (IL) | 2024-05-02 | — | — | WO | disclosed |
| US-20240132455-A1 | CERTAIN (2S)-N-[(1S)-1-CYANO-2-PHENYLETHYL]-1,4-OXAZEPANE-2-CARBOXAMIDES AS DIPEPTIDYL PEPTIDASE 1 INHIBITORS | ASTRAZENECA AB (SE) | 2024-04-25 | — | — | US | disclosed |
| US-20240041896-A1 | CERTAIN (2S)-N-[(1S)-1-CYANO-2-PHENYLETHYL]-1,4-OXAZEPANE-2-CARBOXAMIDES FOR TREATING BRONCHIECTASIS | ASTRAZENECA AB (SE) | 2024-02-08 | — | — | US | disclosed |
| US-11814359-B2 | Certain (2s)-n-[(1s)-1-cyano-2-phenylethyl]-1,4-oxazepane-2-carboxamides as dipeptidyl peptidase 1 inhibitors | ASTRAZENECA AB (SE) | 2023-11-14 | — | — | US | disclosed |
| US-11773069-B2 | Certain (2s)-n-[(1s)-1-cyano-2-phenylethyl]-1,4-oxazepane-2-carboxamides as dipeptidyl peptidase 1 inhibitors | ASTRAZENECA AB (SE) | 2023-10-03 | — | — | US | disclosed |
| US-20230278969-A1 | CERTAIN (2S)-N-[(1S)-1-CYANO-2-PHENYLETHYL]-1,4-OXAZEPANE-2-CARBOXAMIDES AS DIPEPTIDYL PEPTIDASE 1 INHIBITORS | BIOPHARMA CREDIT PLC (GB) | 2023-09-07 | — | — | US | disclosed |
| US-11744822-B2 | Reducing tumor burden by administering CCR1 antagonists in combination with PD-1 inhibitors or PD-L1 inhibitors | CHEMOCENTRYX, INC. (US) | 2023-09-05 | — | — | US | disclosed |
| WO-2008147815-A1 | 3-(IMIDAZOLYL)-PYRAZOLO[3,4-B]PYRIDINES | CHEMOCENTRYX, INC. (US) | 2008-12-04 | — | — | WO | disclosed |
| WO-2008147815-A1 | 3-(IMIDAZOLYL)-PYRAZOLO[3,4-B]PYRIDINES | CHEMOCENTRYX, INC. (US) | 2008-12-04 | — | — | WO | disclosed |
| US-20080300257-A1 | 3-(IMIDAZOLYL)-PYRAZOLO[3,4-b]PYRIDINES | CHEMOCENTRYX, INC. (US) | 2008-12-04 | — | — | US | disclosed |
| US-20080300257-A1 | 3-(IMIDAZOLYL)-PYRAZOLO[3,4-b]PYRIDINES | CHEMOCENTRYX, INC. (US) | 2008-12-04 | — | — | US | disclosed |
| US-20080300257-A1 | 3-(IMIDAZOLYL)-PYRAZOLO[3,4-b]PYRIDINES | CHEMOCENTRYX, INC. (US) | 2008-12-04 | — | — | US | disclosed |
| WO-2008147822-A1 | AZAINDAZOLE COMPOUNDS AND METHODS OF USE | CHEMOCENTRYX, INC. (US) | 2008-12-04 | — | — | WO | disclosed |
| WO-2008147822-A1 | AZAINDAZOLE COMPOUNDS AND METHODS OF USE | CHEMOCENTRYX, INC. (US) | 2008-12-04 | — | — | WO | disclosed |
| US-20080058341-A1 | AZAINDAZOLE COMPOUNDS AND METHODS OF USE | CHEMOCENTRYX, INC. | 2008-03-06 | — | — | US | disclosed |
| US-20080058341-A1 | AZAINDAZOLE COMPOUNDS AND METHODS OF USE | CHEMOCENTRYX, INC. | 2008-03-06 | — | — | US | disclosed |
| US-20080058341-A1 | AZAINDAZOLE COMPOUNDS AND METHODS OF USE | CHEMOCENTRYX, INC. | 2008-03-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240132455-A1 | CERTAIN (2S)-N-[(1S)-1-CYANO-2-PHENYLETHYL]-1,4-OXAZEPANE-2-CARBOXAMIDES AS DIPEPTIDYL PEPTIDASE 1 INHIBITORS | DPP4, DPP7, DPEP1 | CCR1 174/4885CYP2C19 601/4885KCNH2 2478/4885 |
| US-11773069-B2 | Certain (2s)-n-[(1s)-1-cyano-2-phenylethyl]-1,4-oxazepane-2-carboxamides as dipeptidyl peptidase 1 inhibitors | DPP4, DPP7, DPEP1 | CCR1 175/4885CYP2C19 628/4885KCNH2 2475/4885 |
| US-20080058341-A1 | AZAINDAZOLE COMPOUNDS AND METHODS OF USE | CCR1, CCR3, CCR4 | CCR1 1/4885CYP2C19 2476/4885KCNH2 4629/4885 |
| US-12054465-B2 | Certain (2S)-N-[(1S)-1-cyano-2-phenylethyl]-1,4-oxazepane-2-carboxamides as dipeptidyl peptidase 1 inhibitors | DPP4, DPP7, DPEP1 | CCR1 174/4885CYP2C19 601/4885KCNH2 2478/4885 |
| US-20080300257-A1 | 3-(IMIDAZOLYL)-PYRAZOLO[3,4-b]PYRIDINES | CCR1, CCR3, CCR4 | CCR1 1/4885CYP2C19 3044/4885KCNH2 4405/4885 |
| US-20250228870-A1 | CERTAIN (2S)-N-[(1S)-1-CYANO-2-PHENYLETHYL]-1,4-OXAZEPANE-2-CARBOXAMIDES FOR TREATING BRONCHIECTASIS | DPEP1, TPP1, DPP9 | CCR1 58/4885CYP2C19 1046/4885KCNH2 1139/4885 |
| US-11814359-B2 | Certain (2s)-n-[(1s)-1-cyano-2-phenylethyl]-1,4-oxazepane-2-carboxamides as dipeptidyl peptidase 1 inhibitors | DPP4, DPP7, DPEP1 | CCR1 170/4885CYP2C19 674/4885KCNH2 2278/4885 |
| US-11744822-B2 | Reducing tumor burden by administering CCR1 antagonists in combination with PD-1 inhibitors or PD-L1 inhibitors | CCR1, CCRL2, CCR3 | CCR1 1/4885CYP2C19 4406/4885KCNH2 4784/4885 |
| US-20230278969-A1 | CERTAIN (2S)-N-[(1S)-1-CYANO-2-PHENYLETHYL]-1,4-OXAZEPANE-2-CARBOXAMIDES AS DIPEPTIDYL PEPTIDASE 1 INHIBITORS | DPP4, DPP7, DPEP1 | CCR1 175/4885CYP2C19 628/4885KCNH2 2475/4885 |
| US-20240041896-A1 | CERTAIN (2S)-N-[(1S)-1-CYANO-2-PHENYLETHYL]-1,4-OXAZEPANE-2-CARBOXAMIDES FOR TREATING BRONCHIECTASIS | DPEP1, TPP1, DPP9 | CCR1 61/4885CYP2C19 1001/4885KCNH2 1305/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.